Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318901 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
A Phase 1 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02318901: Clinical Trial Phase 1 study, sponsored by Western Regional Medical Center.
NCT02318901 is a Phase 1 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02318901, a Phase 1 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
There will be two phase II cohorts for pembro plus trastuzumab: one cohort will be for patients with unresectable HER2 overexpressing gastric or GEJ cancers, the other cohort will be for patients with HER2 overexpressing metastatic breast cancer (MBC). The pembro plus ado-trastuzumab emtansine phase II arm will be for patients with HER2 overexpressing MBC. There will be two phase II cohorts for pembro plus cetuximab: one cohort will be for patients with HNSCC, the other cohort will be for patients with K-ras, B-raf, N-ras wildtype metastatic CRC.
Interventions
- DRUG Pembrolizumab
- DRUG Trastuzumab
- DRUG Cetuximab
- DRUG ado-trastuzumab emtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02318901
The ClinicalTrials.gov registry entry for NCT02318901 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Regional Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02318901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02318901 about?
NCT02318901 is a clinical study titled "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer". There will be two phase II cohorts for pembro plus trastuzumab: one cohort will be for patients with unresectable HER2 overexpressing gastric or GEJ cancers, the other cohort will be for patients with HER2 overexpressing metastatic breast cancer (MBC). The pembro plus ado-trastuzumab emtansine phase...
What is the current status of trial NCT02318901?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-10. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02318901?
The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Cetuximab (DRUG), ado-trastuzumab emtansine (DRUG).
Who is sponsoring clinical trial NCT02318901?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.